1. PAH and Prostacyclin Pathways in Focus

3. Program Goals

5. Therapies Targeting the Prostacyclin Pathway

6. Case Study 1

7. Case Study Ms PM, 26 Years Old

8. Case Study 1 Assessment

11. GRIPHON Primary Endpoint

12. GRIPHON: Primary Endpoint Composite of Death or a Complication Related to PAH Up to the End of the Treatment Period

14. Case 1 Conclusion

15. Case Study 2 Ms RG, 46 Years Old

16. Case 2 Assessment

17. Parenteral Prostacyclin

19. TRIUMPH Change in 6MWD With Inhaled Treprostinil

20. Case 2 Summary Parenteral vs Inhaled Prostanoid Therapy

21. Survival in Patients Treated With First-Line Bosentan Who Subsequently Received Prostanoid Therapy

22. Case Study 3

23. Case Study 3 Ms KC (cont)

24. Case Study 3 Ms. KC (cont)

25. Recently Diagnosed Functional Class IV Patients

26. REVEAL REGISTRY Medication Use at Time of Death in FC IV Patients

27. Upfront Triple Combination Therapy in PAH

28. Efficacy of Triple Combination Therapy Regimen in Patients With Severe PAH

29. Long-Term Follow-Up of Initial Triple Combination Therapy

30. Concluding Remarks

31. Abbreviations

32. Abbreviations (cont)